196 related articles for article (PubMed ID: 7878854)
1. Effects of fialuridine on hepatitis B immune globulin pharmacokinetics following orthotopic liver transplant for chronic hepatitis B viral-induced cirrhosis.
McGory RW; Ishitani MB; Oliveira WM; Stevenson WC; Dickson RC; Caldwell SH; Pruett TL
Transplant Proc; 1995 Feb; 27(1):1213-4. PubMed ID: 7878854
[No Abstract] [Full Text] [Related]
2. Hepatitis B immune globulin dose requirements following orthotopic liver transplantation for chronic hepatitis B cirrhosis.
McGory R; Ishitani M; Oliveira W; Stevenson W; McCullough C; Pruett T
Transplant Proc; 1996 Jun; 28(3):1687-8. PubMed ID: 8658840
[No Abstract] [Full Text] [Related]
3. Immunoprophylaxis for hepatitis B virus reinfection after liver transplantation.
Jeng LB; Lee WC; Yeh DS; Wang CC; Wang KL; Chen SC; Chen MF; Chien RN; Chiu CT; Lin DY
Transplant Proc; 1994 Aug; 26(4):2243-4. PubMed ID: 8066736
[No Abstract] [Full Text] [Related]
4. Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after liver transplantation.
Ben-Ari Z; Zemel R; Kazetsker A; Fraser G; Tur-Kaspa R
Am J Gastroenterol; 1999 Mar; 94(3):663-7. PubMed ID: 10086648
[TBL] [Abstract][Full Text] [Related]
5. Allograft biopsies in situ hybridization HBVDNA detection of serum HBs Ag-repositive patients treated with anti-HBV immunoprophylaxis after liver transplantation for HBV cirrhosis.
Reynès M; Tricottet V; Samuel D; Sebagh M; Bismuth A; Arulnaden J; Brechot C; Bismuth H
Transplant Proc; 1993 Feb; 25(1 Pt 2):1347-8. PubMed ID: 8442139
[No Abstract] [Full Text] [Related]
6. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
Chan HL; Chui AK; Lau WY; Chan FK; Wong ML; Tse CH; Rao AR; Wong J; Sung JJ
J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406
[TBL] [Abstract][Full Text] [Related]
7. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.
McKenzie R; Fried MW; Sallie R; Conjeevaram H; Di Bisceglie AM; Park Y; Savarese B; Kleiner D; Tsokos M; Luciano C
N Engl J Med; 1995 Oct; 333(17):1099-105. PubMed ID: 7565947
[TBL] [Abstract][Full Text] [Related]
8. [Dynamics of HBV-DNA level in acute hepatitis B].
Zhao H; Cao JH; Tian GS
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Jun; 17(2):159-61. PubMed ID: 12870000
[TBL] [Abstract][Full Text] [Related]
9. Successful retransplantation for recurrent posttransplant hepatitis B virus infection in the primary allograft.
Ishitani M; McGory R; Dickson R; Caldwell S; Bickston S; McCullough C; Pruett T
Transplant Proc; 1996 Jun; 28(3):1714-6. PubMed ID: 8658852
[No Abstract] [Full Text] [Related]
10. Residual hepatitis B virus particles in liver transplant recipients receiving lamivudine: PCR quantitation of HBV DNA and ELISA of preS1 antigen.
Petit MA; Buffello-Le Guillou D; Roche B; Dussaix E; Duclos-Vallée JC; Féray C; Samuel D
J Med Virol; 2001 Nov; 65(3):493-504. PubMed ID: 11596084
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of hepatitis B].
Telegdy L
Orv Hetil; 2004 Nov; 145(45):2293-6. PubMed ID: 15573894
[TBL] [Abstract][Full Text] [Related]
12. Preventing infection-associated cancer: from bench to hillside.
Goedert JJ
J Natl Cancer Inst; 2005 Feb; 97(4):245-6. PubMed ID: 15713953
[No Abstract] [Full Text] [Related]
13. Clinical course of four patients receiving the experimental antiviral agent fialuridine for the treatment of chronic hepatitis B infection.
Stevenson W; Gaffey M; Ishitani M; McCullough C; Dickson R; Caldwell S; Lobo P; Pruett T
Transplant Proc; 1995 Feb; 27(1):1219-21. PubMed ID: 7878856
[No Abstract] [Full Text] [Related]
14. Combination hepatitis B immune globulin and lamivudine versus hepatitis B immune globulin monotherapy in preventing recurrent hepatitis B virus infection in liver transplant recipients.
Ben-Ari Z; Mor E; Bar-Nathan N; Shaharabani E; Shapira Z; Tur-Kaspa R
Transplant Proc; 2003 Mar; 35(2):609-11. PubMed ID: 12644066
[No Abstract] [Full Text] [Related]
15. Evolution of wild-type and precore mutant HBV infection after liver transplantation.
Torre F; Wong PY; Macartney M; Williams R; Naoumov NV
J Med Virol; 1999 Sep; 59(1):5-13. PubMed ID: 10440801
[TBL] [Abstract][Full Text] [Related]
16. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine.
Sponseller CA; Bacon BR; Di Bisceglie AM
Liver Transpl; 2000 Nov; 6(6):715-20. PubMed ID: 11084057
[TBL] [Abstract][Full Text] [Related]
17. Milan multicenter experience in 96 liver transplants for hepatitis B virus-related cirrhosis.
Caccamo L; Belli LS; Mazzaferro V; Colledan M; Alberti A; Regalia E; Fassati LR; Ideo G; Rubino A; Belli L
Transplant Proc; 1994 Dec; 26(6):3585-7. PubMed ID: 7998283
[No Abstract] [Full Text] [Related]
18. [Evaluation of the changes of HBV serum markers and HBV DNA and the effects of perioperative factors after liver transplantation].
Tang YM; Chen GH; He XS; Zhu XF; Chen MH
Zhonghua Gan Zang Bing Za Zhi; 2005 Mar; 13(3):164-7. PubMed ID: 15760545
[TBL] [Abstract][Full Text] [Related]
19. Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study.
Ikeda K; Kobayashi M; Someya T; Saitoh S; Hosaka T; Akuta N; Suzuki F; Suzuki Y; Arase Y; Kumada H
J Viral Hepat; 2009 Jun; 16(6):437-43. PubMed ID: 19226331
[TBL] [Abstract][Full Text] [Related]
20. Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection.
Tennant BC; Baldwin BH; Graham LA; Ascenzi MA; Hornbuckle WE; Rowland PH; Tochkov IA; Yeager AE; Erb HN; Colacino JM; Lopez C; Engelhardt JA; Bowsher RR; Richardson FC; Lewis W; Cote PJ; Korba BE; Gerin JL
Hepatology; 1998 Jul; 28(1):179-91. PubMed ID: 9657111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
